Article
Immunology
Tingting Han, Juan Xie, Xiaosu Zhao, Meng Lv, Yingjun Chang, Lanping Xu, Yu Wang, Xiaohui Zhang, Kaiyan Liu, Xiao-Jun Huang, Xiang-Yu Zhao
Summary: This retrospective study evaluated the association of CMV infection with leukemia relapse and its potential mechanism. The results demonstrated that CMV infection was associated with lower survival rates, higher treatment-related mortality, and higher relapse rates. Moreover, CMV infection may promote the recovery and differentiation of NK cells.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
(2022)
Article
Biophysics
Elizabeth Krieger, Rehan Qayyum, Armand Keating, Amir Toor
Summary: In unrelated donor hematopoietic cell transplant for AML, donors with higher inhibitory KIR content provide relapse protection but may come with increased transplant-related mortality, typically characterized by KIR haplotype B. Clinical trials with higher iKIR content in donors alongside strategies to reduce TRM should be considered for optimal outcomes.
BONE MARROW TRANSPLANTATION
(2021)
Article
Hematology
Mesire Aydin, David C. C. de Leeuw, Caroline E. E. Rutten, Otto J. J. Visser, Man Wai Tang, Cinthy van Roessel, Jeroen J. W. Janssen, Bart J. J. Biemond, Arjan A. A. van de Loosdrecht, Mette D. D. Hazenberg, Ellen Meijer, Erfan Nur
Summary: A systematic comparison of transplantation outcomes between two lymphocyte-depleting strategies, ATG and PTCy, in non-myeloablative conditioning for allogeneic haematopoietic stem cell transplantation revealed a significantly lower rate of acute GvHD in the PTCy group compared to the ATG group.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Sarah Haebe, Alessia Fraccaroli, Elena Stauffer, Dusan Prevalsek, Anna K. Zoellner, Heidrun Drolle, Hans-Joachim Stemmler, Martin Dreyling, Michael von Bergwelt-Baildon, Johanna Tischer
Summary: Haplo-HSCT has emerged as a valuable alternative for patients without an available HLA-matched donor, with similar outcomes to MRD and URD transplantations. Haplo-HSCT also has a lower incidence of GvHD and better survival rates.
Article
Hematology
Mahasweta Gooptu, Rizwan Romee, Andrew St Martin, Mukta Arora, Monzr Al Malki, Joseph H. Antin, Christopher N. Bredeson, Claudio G. Brunstein, Saurabh Chhabra, Ephraim J. Fuchs, Nilanjan Ghosh, Michael R. Grunwald, Christopher G. Kanakry, Natasha Kekre, Jospeh P. McGuirk, Ian K. McNiece, Rohtesh S. Mehta, Marco Mielcarek, Fillipo Milano, Dipenkumar Modi, Ran Reshef, Scott R. Solomon, Mark A. Schroeder, Edmund K. Waller, Yoshiro Inamoto, Robert J. Soiffer, Mary Eapen
Summary: After comparing outcomes of 2036 haploidentical and 284 matched unrelated donor (MUD) transplantations with posttransplant cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis, it was found that MUD transplants had lower acute GVHD and nonrelapse mortality rates, as well as higher disease-free and overall survival, especially in recipients of reduced-intensity regimens. However, no significant differences were observed in patients receiving myeloablative conditioning regimens, highlighting the importance of donor-recipient HLA matching for allogeneic transplantation.
Article
Immunology
Hongfeng Huang, Qixia Shen, Jingyi Zhou, Xiuyan Yang, Qiuqin Cai, Jia Shen, Shi Feng, Wenqing Xie, Hong Jiang, Jianghua Chen
Summary: The clinical experience demonstrates the efficacy of non-myeloablative conditioning protocol in inducing tolerance in HLA identical patients, and complete chimerism may be a risk factor for GVHD.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
David Cruz, Rocio Rodriguez-Romanos, Marta Gonzalez-Bartulos, Irene Garcia-Cadenas, Rafael de la Camara, Inmaculada Heras, Ismael Buno, Nazly Santos, Natalia Lloveras, Pilar Velarde, Esperanza Tuset, Carmen Martinez, Marcos Gonzalez, Guillermo F. F. Sanz, Christelle Ferra, Antonia Sampol, Rosa Coll, Jose A. A. Perez-Simon, Javier Lopez-Jimenez, Manuel Jurado, David Gallardo
Summary: In this study, the association between LAG3 gene polymorphism and the clinical outcomes of alloHSCT was investigated. The results showed that patients transplanted from donors with the TT genotype had a higher incidence of severe acute GVHD and worse overall survival, disease-free survival, and transplant-related mortality. The combination of LAG3 and PDCD1 genotypes allowed for a good stratification of the risk of acute GVHD, TRM, OS, and DFS.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Cell & Tissue Engineering
Guangyu Sun, Baolin Tang, Kaidi Song, Yue Wu, Meijuan Tu, Xiang Wan, Wen Yao, Liangquan Geng, Ping Qiang, Xiaoyu Zhu
Summary: This study compared the outcomes of UCBT and MST in the treatment of adult B-ALL patients. The results showed that UCBT had slower hematopoietic recovery but lower incidence of extensive cGVHD. The NRM, relapse, DFS, and GRFS were comparable between MST and UCBT recipients, but UCBT showed better OS for patients with long-term survival.
STEM CELL RESEARCH & THERAPY
(2022)
Article
Oncology
Raynier Devillier, Boris Calmels, Sophie Guia, Mohammed Taha, Cyril Fauriat, Bechara Mfarrej, Geoffroy Venton, Eric Vivier, Daniel Olive, Christian Chabannon, Didier Blaise, Sophie Ugolini
Summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective curative option for high-risk hematologic malignancies, but disease recurrence remains a critical issue. NK cell-based immunotherapies offer a promising approach to enhance anti-tumor effects without triggering graft-versus-host disease. This clinical trial demonstrates the safety and potential efficacy of prophylactic donor-derived IL-2 activated NK cell infusion after allo-HSCT for patients with hematologic malignancies.
Article
Hematology
Mohamed A. Kharfan-Dabaja, Myriam Labopin, Eolia Brissot, Nicolaus Kroger, Juergen Finke, Fabio Ciceri, Eric Deconinck, Didier Blaise, Patrice Chevallier, Martin Gramatzki, Arnold Ganser, Matthias Stelljes, Matthias Edinger, Bipin Savani, Annalisa Ruggeri, Jaime Sanz, Arnon Nagler, Mohamad Mohty
Summary: The study compared outcomes of 455 adults with relapsed AML undergoing second allo-HCT, with no significant difference in overall survival between those receiving MUD or haploidentical donors. It was found that receiving the second allo-HCT in complete remission led to the best overall survival.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Hematology
Maria Queralt Salas, Paola Charry, Alexandra Pedraza, Nuria Martinez-Cibrian, Maria Teresa Solano, Ariadna Domenech, Maria Suarez-Lledo, Meritxell Nomdedeu, Joan Cid, Miquel Lozano, Noemi de-LLobet, Jordi Arcarons, Laura Rosinol, Gonzalo Gutierrez-Garcia, Enric Carreras, Jordi Esteve, Alvaro Urbano-Ispizua, Francesc Fernandez-Aviles, Montserrat Rovira, Carmen Martinez
Summary: This study compared the outcomes of PTCY-tacrolimus (TK) prophylaxis and conventional GVHD prophylaxis in patients aged >50 years undergoing peripheral blood alloHSCT. The results showed that the PTCY-TK group had lower incidence of acute and chronic GVHD and better GVHD-free/relapse-free survival.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Immunology
Guangyang Weng, Zhiping Fan, Huiwen Xue, Fen Huang, Na Xu, Hua Jin, Sijian Yu, Zhixin Ye, Jingchao Fan, Li Xuan, Qifa Liu
Summary: The study found that haploidentical donor stem cell transplantation had a lower incidence of bronchiolitis obliterans syndrome (BOS) compared to HLA-matched sibling donor stem cell transplantation. Additionally, the use of antithymocyte globulin (ATG) and mixed grafts may be protective factors in reducing the incidence of BOS.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Hematology
Rohtesh S. Mehta, Rima M. Saliba, Sassine Ghanem, Amin M. Alousi, Gabriela Rondon, Paolo Anderlini, Gheath Al-Atrash, Qaiser Bashir, Chitra M. Hosing, Jin S. Im, Partow Kebriaei, Issa Khouri, David Marin, Yago Nieto, Amanda Olson, Betul Oran, Uday R. Popat, Muzaffar H. Qazilbash, Jeremy Ramdial, Neeraj Saini, Samer A. Srour, Richard E. Champlin, Katayoun Rezvani, Elizabeth J. Shpall
Summary: Despite the use of post-transplantation cyclophosphamide (PTCy), haploidentical donor hematopoietic cell transplantation (HCT) still has inferior outcomes compared to HLA-matched donor HCT. The haploidentical group had higher nonrelapse mortality and poorer progression-free survival and overall survival compared to the matched unrelated donor group. Relapse was the most common cause of death in all groups. The haploidentical group also had higher risk of infections, hemorrhagic cystitis, cardiovascular toxicities, and slower reconstitution of certain immune cells.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Oncology
Kavita Raj, Dirk-Jan Eikema, Vipul Sheth, Linda Koster, Liesbeth C. de Wreede, Didier Blaise, Carmela Di Grazia, Yener Koc, Victoria Potter, Patrice Chevallier, Lucia Lopez-Corral, Depei Wu, Stephan Mielke, Johan Maertens, Ellen Meijer, Anne Huynh, Jakob Passweg, Thomas Luft, Jose Antonio Perez-Simon, Fabio Ciceri, Agnieszka Piekarska, G. Hayri Ozsan, Nicolaus Kroeger, Marie Robin, Ibrahim Yakoub-Agha
Summary: In the treatment of myelodysplastic syndromes, this study compared the outcomes of matched sibling donors with haplo-identical donors for allogeneic hematopoietic cell transplantation. The results showed that matched sibling donors had better overall survival and progression-free survival, but higher relapse rates compared to haplo-identical donors. The non-relapse mortality rate was lower with matched sibling donors, while the incidence of chronic graft-versus-host disease was higher.
BLOOD CANCER JOURNAL
(2022)
Article
Oncology
Pietro Crivello, Esteban Arrieta-Bolanos, Meilun He, Tao Wang, Stephanie Fingerson, Shahinaz M. Gadalla, Sophie Paczesny, Steven G. E. Marsh, Stephanie L. J. Lee, Stephen R. Spellman, Yung-Tsi Bolon, Katharina Fleischhauer
Summary: This study found that immunopeptidome divergence is a determinant of T-cell alloreactivity and clinical tolerability in single class I HLA-mismatched unrelated donor hematopoietic cell transplantation. Using hierarchical clustering of peptide-binding motifs, the authors classified 68.1% of the HLA-mismatched transplants as matched or mismatched. Mismatched transplants were associated with lower overall survival.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
